CCI approves GSK, Pfizer consumer healthcare JV formation

24 May 2019 Evaluate

The Competition Commission of India (CCI) has approved the formation of a joint venture (JV) for consumer healthcare products by pharmaceutical giants Glaxosmithkline (GSK) and Pfizer. In December 2018, GSK had reached an agreement with Pfizer to combine their consumer health businesses into a new JV with combined sales of around $12.7 billion (around Rs 88,900 crore).

The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK. After the deal, GSK will have a majority controlling equity interest of 68 percent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 percent.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer Share Price

4266.90 -31.95 (-0.74%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.